Close Menu

NEW YORK – Proteomics firm Nautilus Biotechnology plans to list on the Nasdaq through a merger with special purpose acquisition company Arya Sciences Acquisition Corp III.

Seattle-based Nautilus has entered a definitive merger agreement with Arya and is expected to receive $350 million in proceeds through the deal, including a $200 million private investment in public equity (PIPE) transaction at $10 per share from investors led by Perceptive Advisors, an affiliate of Arya III's sponsor.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.

Researchers in France are developing a new, fast test for SARS-CoV-2 that initial testing indicates may be highly accurate, the Guardian says.

In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.